NCT07087158 2025-07-28
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
Clinical Trials
20 trialsNCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT01330966 2023-03-10
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Emerald Clinical Inc.
Phase 2 Completed
NCT01759303 2021-04-13
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Emerald Clinical Inc.
Phase 2 Terminated
NCT01956669 2020-08-12
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Novartis
Phase 2 Completed
NCT00281632 2018-09-17
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00615524 2018-01-12
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT00256880 2017-01-18
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Completed
NCT02367651 2016-10-12
Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma
GlaxoSmithKline
Phase 2 Withdrawn
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00297258 2016-02-03
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
GlaxoSmithKline
Phase 2 Completed
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01227928 2015-03-03
Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
GlaxoSmithKline
Phase 2 Completed
NCT00549328 2014-11-19
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00849472 2014-03-04
Treatment With Pazopanib for Neoadjuvant Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00871403 2013-06-20
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00558103 2013-02-04
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00367679 2012-06-12
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00561795 2012-03-22
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Phase 2 Completed